![Mark Enyedy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 805 277 $ al 31/12/2025
Mark Joseph Enyedy is currently an Independent Director at BioMarin Pharmaceutical, Inc. since 2023, an Independent Director at Charles River Laboratories International, Inc. starting in 2025, and an Independent Outside Director at Astellas Pharma, Inc. starting in 2025.
Formerly, Mr. Enyedy was President, Chief Executive Officer & Director at ImmunoGen, Inc. from 2016 to 2024; Chief Executive Officer & Director at Proteostasis Therapeutics, Inc. from 2011 to 2013; Independent Director at Keryx Biopharmaceuticals, Inc. from 2017 to 2018; Independent Director at Akebia Therapeutics, Inc. from 2018 to 2021; Director at Biotechnology Innovation Organization; Director at American Cancer Society, New England Division, Inc.; Independent Director at Fate Therapeutics, Inc. from 2013 to 2018; Independent Director at LogicBio Therapeutics, Inc. from 2020 to 2022; Independent Non-Executive Director at Ergomed Group Ltd. from 2021 to 2023; SVP, President-Transplant & Multiple Sclerosis at Genzyme Corp.
from 2011 to 2012; Executive VP & Head-Corporate Development at Shire Plc from 2014 to 2016; and Associate at Palmer & Dodge LLP.
Education includes undergraduate studies at Northeastern University and graduate studies at Harvard Law School.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/05/2025 | 13.550 ( 0,01 % ) | 805 277 $ | 31/12/2025 |
| Empresas | Cargo | Inicio |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Director/Miembro de la Junta | 27/12/2023 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Director/Miembro de la Junta | 20/05/2025 |
| ASTELLAS PHARMA INC. | Director/Miembro de la Junta | 19/06/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Director Ejecutivo | 01/01/2024 |
| ERGOMED | Director/Miembro de la Junta | 13/11/2023 |
| LOGICBIO THERAPEUTICS, INC. | Director/Miembro de la Junta | 16/11/2022 |
| AKEBIA THERAPEUTICS, INC. | Director/Miembro de la Junta | 02/06/2021 |
| KERYX BIOPHARMACEUTICALS | Director/Miembro de la Junta | 12/12/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 17 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. Develops anticancer therapeutics | |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Charles River Laboratories International, Inc.
 Charles River Laboratories International, Inc. Miscellaneous Commercial ServicesCommercial Services Provides laboratory testing and research services on a contract basis | Commercial Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Develops and manufactures specialty therapeutic, surgical and diagnostic products | Health Technology |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Shire Plc
 Shire Plc Develops and markets medicines for patients with rare diseases | |
Palmer & Dodge LLP
 Palmer & Dodge LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma, Inc.
 Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Akebia Therapeutics, Inc.
 Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Fate Therapeutics, Inc.
 Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Develops disease-modifying therapeutics for orphan and neurodegenerative diseases | Health Technology |
American Cancer Society, New England Division, Inc. | |
Harvard Law School
 Harvard Law School Functions as a College/University | |
Ergomed Plc
 Ergomed Plc Engages in research and development of drugs for oncology & rare diseases | |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Develops genetic medicine for pediatric patients and rare diseases |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
MarketScreener is also available in this country: United States.
Switch edition
